Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)

•PD-L1 ≥ 1% is expressed in 16% of stage IV LCNEC, 5% has expression ≥50%.•PD-L1 staining in LCNEC is comparable to values in SCLC, but lower than in NSCLC.•No difference in PD-L1 expression is found in RB1 mutated and RB1 wildtype subgroups.•Expression of PD-L1 (tumor cells) and CD8 (tumor infiltrating cells) is associated.•Overall survival is prolonged in patients with PD-L1+ and CD8+ LCNEC.